Overdiagnosis estimates have varied substantially, causing confusion. The discussions have been complicated by the fact that population and study design have varied substantially between studies. To help assess the impact of study design choices on the estimates, we compared them on a single population. A cohort study from Funen County, Denmark, recently suggested little (~1%) overdiagnosis. It followed previously screened women for up to 14 years after screening had ended. Using publically available data from Funen, we recreated the designs from five high-estimate, highly cited studies from various countries. Selected studies estimated overdiagnosis to be 25-54%. Their designs were adapted only to the extent that they reflect the start of screening in Funen in 1993. The reanalysis of the Funen data resulted in overdiagnosis estimates that were remarkably similar to those from the original high-estimate age-period studies, 21-55%. In additional analyses, undertaken to elucidate the effect of the individual components of the study designs, overdiagnosis estimates were more than halved after the most likely changes in the background risk were accounted for and decreased additionally when never-screened birth cohorts were excluded from the analysis. The same data give both low and high estimates of overdiagnosis, it all depends on the study design. This stresses the need for a careful scrutiny of the validity of the assumptions underpinning the estimates. Age-period analyses of breast cancer overdiagnosis suggesting very high frequencies of overdiagnosis rested on unmet assumptions. This study showed that overdiagnosis estimates should in the future be requested to adequately control for the background risk and include an informative selection of the studied population to achieve valid and comparable estimates of overdiagnosis.
long-term follow-up offered the most plausible estimates of overdiagnosis, 11-19% depending on the chosen perspective. 1, 2 The reliance on randomized trials-undertaken some 30-40 years ago-in this and other reviews, for example, that published by the Cochrane Collaboration, 10 has, however, been criticized because continued screening in the intervention group after the trials had ended may have minimized the observed compensatory drop and thereby overestimated overdiagnosis. Without more up-to-date RCTs, estimates of overdiagnosis have to be based on observational studies.
In present-day routine settings, estimates of overdiagnosis from observational studies have unfortunately varied substantially. The EUROSCREEN review showed two groups of estimates: one with <10% overdiagnosis, and one with >30% (mean: 44%, one study 20%). 11 Three more recent reviews [12] [13] [14] identified additional studies with similarly high estimates. Some of the reviewed studies used the population and others used the women's perspective; nevertheless, this can only partly explain the differences in the estimates.
Comparison of overdiagnosis estimates is complicated by the fact that the studies differed both in their populations and in study designs. The variability seems disconcerting even for experts, 2, 15 let alone for women considering their screening participation. To reduce this complexity, Etzioni and Gulati recommended using multiple study designs on the same data, as "a check" of one against the other. 8 The aim of this article is to undertake such a comparison by using data from a single population from Funen County in Denmark and hereby to provide empirical input for an appraisal of the different mammography overdiagnosis study designs.
Material and Methods
The Funen program started inviting women aged 50-69 years biennially in November 1993. Nonprogram screening was infrequent. 16 This program has been evaluated in several studies and recently, Njor et al. 17 estimated overdiagnosis at 1% of all breast cancer cases including ductal carcinoma in situ (DCIS). The study included birth cohorts invited to screening from the start of the program and who had been, after age 70 years, discharged from it for 5-14 years (N 5 24,832 women born in 11 cohorts between November 1923 and October 1934). Cumulative incidence rates in these cohorts were compared to the same cohorts living in nonscreening areas, after taking account of regional differences before screening. A long follow-up after screening that was incorporated into the calculation of the cumulative incidence rates accounted for a potential compensatory drop without having to assume the parameters of lead time distribution or a proportion of nonprogressive lesions. 8 We attempted to compare the results of the published lowestimate study of mammography overdiagnosis in Funen by Njor et al. 17 to the results that would be obtained in case we applied the designs of high-estimate studies to the same data.
High-estimate studies
From four recent reviews, [11] [12] [13] [14] we identified studies that (i) used data from routine screening and (ii) suggested 20% 11 overdiagnosis, and (iii) attempted to estimate a potential compensatory drop by observing women older than the upper age for screening, without statistical modeling of lead time (Table 1 ; Appendix). All five included studies [18] [19] [20] [21] [22] were excess incidence studies that compared observed breast cancer incidence rates at screening and postscreening ages after screening was introduced (study population) to incidence rates before screening or in different but contemporary populations (control population). They all used age-period designs, whereby the selection of birth cohorts into the analysis changed in each calendar year.
Data source
Incidence rates of invasive breast cancer (without DCIS) in 1972-2006 for Funen and Danish nonscreening areas were retrieved from Nordcan. 23 This English-language data source is freely available online and downloadable for further analysis (https://www.ancr.nu/cancer-data/pc-nordcan/). Countyspecific data were only available until 2006 because in 2007 Denmark underwent an administrative reorganization. These data were fully consistent with those used for the lowestimate study by Njor et al. 17 Nordcan reports the absolute numbers of cancer cases and incidence rates; we used those to estimate population sizes.
Statistical analysis
We applied the designs of the included high-estimate studies to data from Funen. As a check of our understanding of the study design descriptions, we tried to reproduce the published estimates using Nordcan data for the specific countries. For our reanalyses, we defined study and control populations in the exact same way as the high-estimate studies, but relative to the start of screening implementation in Funen. Once considered from the same starting point, Table 2 shows how What's new? Breast cancer screening can lead to better survival, but it also increases the risk of overdiagnosis. Significant variability in overdiagnosis estimates has been disconcerting to both experts and women considering their screening participation. Here, the authors reproduced the analyses made in several previous studies to estimate overdiagnosis using a single recent data source. Estimates ranged widely, from 1% to 55%. However, high estimates were more than halved when accounting for changes in background risk, and further decreased when excluding never-screened birth cohorts. Thus, considering underlying study assumptions is important to produce more informative overdiagnosis estimates, and potentially avoid unwarranted confusion. Shaded area: 1992 was last full prescreening year; screening was implemented in November 1993 but few women were screened in the two months before the end of the year; and 1994 was considered the first full year of screening. X 5 prescreening period (control population). O 5 screening period (study population). 1 Norwegian substudy. 3 End of prescreening period: last prescreening year. 4 End of prescreening period: last year before an abrupt increase in the incidence. 
Results
All five high-estimate studies estimated overdiagnosis by the excess incidence calculated by comparing the incidence in the screening period (i.e., the incidence that was observed after the start of screening) to the incidence that would be expected in the screening period had screening not been implemented; and thereafter adjusting for any compensatory drop at postscreening ages. The estimation of the expected incidence in the screening period had screening not been implemented as well as the method used to adjust for any compensatory drop, varied by study, and the respective approaches are described below for each study.
Zahl et al., 2004
Zahl et al. 19 estimated overdiagnosis after the start of screening in Norway (1998-1999; Akershus, Oslo, Rogaland and Hordaland [AORH] counties) and Sweden (1997 Sweden ( -2000 . The expected incidence in the screening period was estimated by assuming that the trends in the screening and non-screening age groups have developed similarly over time since 1991 and 1971, respectively. Screening started in 1996 and 1986, respectively. No adjustment for a compensatory drop was made as the nonsignificant incidence decline at age 70 years in one area and incidence increases in the other areas were interpreted as no or a very small compensatory drop. Overdiagnosis was therefore estimated-after adjusting for trends at ages 30-49 and 70 years-by the excess incidence at age 50-69 several years after the start of screening relative to the prescreening period, that is, 54% in Norway and 45% in Sweden (Table 3) .
Replicating the Norwegian definitions of the prescreening and screening periods so that they corresponded to Funen where screening started in 1993, defined 1988-1992 as the prescreening period and 1996-1997 as the screening period ( Table 2 ). In Funen, the incidence at 50-69 years increased by 41% more from 1988-1992 to 1996-1997 than it did in the nonscreening age groups, using the authors' calculation method ( Table 4 ). The incidence did not decrease at 70 years (Table 4) . Thus, replicating the method used for the Norwegian substudy, overdiagnosis would be estimated at 41% (Table 3) . Replicating the Swedish substudy, overdiagnosis would be estimated at 46%, that is, the excess increase at 50-69 years from 1979-1992 to 2003-2006 compared to the increase in nonscreening age groups. No decrease was seen at age 70 years.
Jørgensen and Gøtzsche, 2009
Jørgensen and Gøtzsche 21 used published and unpublished data from the United Kingdom, Canada (Manitoba), Australia (New South Wales), Sweden, and Norway (AORH) and estimated overdiagnosis after the start of screening in these countries. The expected incidence in the screening period had screening not been implemented was estimated by a linear extrapolation of the pre-screening incidence until the last year before screening or until the last year before an abrupt incidence increase. The screening period was limited to maximum 10 calendar years after the start of the programs. If no data on DCIS was available, the authors divided the incidence of invasive cancer after the start of screening by 0.9. Any compensatory drop at 70 years of age was included in the calculations. Overall, they estimated overdiagnosis at 52%.
The expected incidence in 2003 for women from Funen aged 50-69 years was 300.0/100,000 (based on extrapolations from the last pre-screening year) or 277.9/100,000 (based on the last year before an abrupt increase in the incidence). The "observed" incidence during screening at 50-69 years was 389.6/100,000 in 2003, using the authors' method of smoothing for yearly fluctuations. The latter incidence was 30-40% Norway 25% (any follow-up) 18% (10 years of follow-up) 52% (2-year follow-up) 21% (6-year follow-up) 13% (10-year follow-up) 1 Excluding DCIS.
above the expected incidence. Applying the same method to age 70-79 years resulted in expected incidence rates of 292.0/ 100,000 and 255.6/100,000, respectively. The "observed" incidence was 248.0/100 000, that is, 3-15% lower than expected. After a correction for DCIS, this gave the final overdiagnosis estimate of 40-55% (Table 3) . If using age Group 70-84 years for the compensatory drop (as done by the authors for some countries), overdiagnosis would be estimated at 40-56% (data not shown).
Jørgensen et al., 2009 22
The authors estimated overdiagnosis in Copenhagen and Funen after the start of screening (1991-2003 and 1994-2003, respectively) . Contrary to the other high-estimate studies, they used data on both the invasive cancer and DCIS cases. The expected incidence in the screening period (1991-2003) had screening not been implemented was estimated by the incidence in nonscreening Danish areas in the same period. Similarly, the difference between the observed and the expected incidence in age Group 70-79 years was used to study the magnitude of the compensatory drop. In 1991-2003, they found an excess (unadjusted) incidence of 35% at age 50-69 years, and no decrease at 70 years. Had they only included invasive breast cancer, they would have found 31% excess incidence (excluding 6% DCIS diagnosed at 50-69 years in the screening areas and 3% DCIS diagnosed in nonscreening areas). If including only years with screening in Funen, 1994-2003, and excluding DCIS, the excess incidence would be 33% (370.0/277.6) at 50-69 years, whereas at 70-79 years, the incidence would be 11% lower (294.5/330.1). Using the authors' method, overdiagnosis was 27% (Table 3) .
Zahl and Maehlen, 2012 18
The authors estimated overdiagnosis in AORH in a 12-year screening period (1998-2009). The expected incidence in the screening period had screening not been implemented was estimated by the observed incidence in the 5-year prescreening period (1991-1995). An observed incidence increase at age 70-79 years was interpreted as an absence of a compensatory drop, wherefore no adjustment for a compensatory drop was made. They found a 50% increase in the incidence at 50-69 years, and therefore, estimated overdiagnosis at 50%.
In Funen, breast cancer incidence increased by 42% (343.1/242.3) at 50-69 years and by 2% (296.8/289.7) at 70-79 years. Using the authors' method, overdiagnosis would be estimated at 42% (Table 3) . 
Kalager et al., 2012 20
The authors estimated overdiagnosis after screening implementation in Norway (including AORH). The expected incidence in the screening period had screening not been implemented was estimated by the incidence in nonscreening areas adjusted for historical differences between the screening and nonscreening areas. The compensatory drop was taken into account, by determining the excess incidence in the age group 50-79 years. At age 50-79 years, they found an excess incidence of 25% in the entire country (including regions with 2-6 years of screening and regions with 10 years of screening), and 18% in AORH where screening first started (10 years of screening). In Funen, the excess incidence at age 50-79 years, in screening areas versus nonscreening areas, was 13% (350.2/ 248.0 vs. 290.5/232.4; Table 3 ) when using data from 10 years after start of screening. Using data from the first 2-6 years of screening would give an excess incidence of 21% (6 years) to 52% (2 years; data not shown).
Breast cancer incidence at 50 years
Data from the early 2000s suggested a negligible amount of opportunistic screening across Denmark. 16 In nonscreening areas, the incidence at 40-49 years decreased by 3% (143.1/ 147.5; Table 4 ) from 1988 to 1992 (prescreening period in Funen) to 1994 to 2003 (screening period in Funen). At 30-49 years, the incidence decreased by 6% (data not shown). At age 50-69 years, however, the incidence increased by 21% (277.6/228.6) in the same nonscreening areas.
Discussion
Our analysis provides an empirical example of how widely differing estimates of overdiagnosis in breast cancer screening can be obtained on the same data, and lends straightforward empirical evidence to substantiate criticism of overdiagnosis study designs. 8, 9, 11 The estimates, based purely on observational data without statistical assumptions of lead time distribution, 8, 9 ranged from 1% to 55%. They were produced from data belonging to the same women and can therefore not all be correct at the same time. This paradox further stresses the need for a critical assessment of the assumptions underlying the most frequently cited (Table 1) approaches to estimating overdiagnosis, and the importance of an agreement between researchers about the methodology for overdiagnosis quantification. Below, we discuss and assess the contribution of two analytical components that are particularly pertinent to purely observational, nonrandomized, studies of mammography overdiagnosis. These are (a) estimating the incidence that would be expected in the absence of screening and (b) valid incorporation of the concept of screening-induced lead time into the analyses through observation of a compensatory drop.
Estimating the expected incidence
Some important risk factors for breast cancer, for example, breast density or overweight, have become more prevalent in recent years, 25, 26 in parallel with screening becoming more widespread. Historic breast cancer incidence rates from unscreened older birth cohorts are, therefore, probably too low 27 and not representative for the currently screened cohorts without further validation.
Jørgensen et al. 22 and Kalager et al. 20 similarly as Njor et al. 17 adjusted the prescreening incidence in screening areas for contemporaneous changes in nonscreening areas. However, the comparability of screening and nonscreening areas has been questioned. 11, 28, 29 For example, Copenhagen (which represented the larger part of the Jørgensen et al.
22 study) showed different trends in the prescreening incidence than did nonscreening areas or Funen alone. 17, 28 In the lowestimate study by Njor et al., 17 the expected incidence in Funen was corrected for trends in nonscreening areas, after verifying that Funen and nonscreening areas were comparable before screening was implemented. Another type of a control population frequently considered to assess the most likely trends at age 50-69 years were women below age 50 years whose risk remained unaffected by screening. 19, 21, 22 Our data on unscreened women, echoing those from other countries, 30, 31 showed a substantial increase at 50-69 but not at <50 years. They argue against uncritical extrapolations of trends at a young to an older age. A substantial increase in the incidence at 50-69 but not at <50 years in nonscreening areas could indicate a substantial amount of opportunistic screening above age 50 years. As shown in a previous study, this was however not the case in the Danish nonscreening areas. 16 The error introduced into an overdiagnosis study by underestimating the expected incidence without screening is measurable. For example, Jørgensen and Gøtzsche estimated the expected incidence through a linear extrapolation of the prescreening incidence. 21 This approach suggested 30-40% excess incidence due to screening in Funen. The same linear extrapolation in nonscreening Danish areas would result in an apparent excess incidence of 12-17%, demonstrating that a linear extrapolation underestimated the true trends unrelated to screening. As another example, the Norwegian study by Zahl and Maehlen 18 assumed a stable risk of breast cancer throughout the last prescreening and screening years. Official cancer registry data for both countries, however, suggested an increasing incidence in the prescreening periods, 23 as did the Danish data. Had these observed trends been considered, overdiagnosis estimates for Funen would have more than halved from 42% to 13% (not tabulated).
Adjustment for a compensatory drop
While it is possible to formally control for the changes in breast cancer risk in an age-period analysis, an adequate adjustment for lead time and compensatory drop is impossible in this design without making additional assumptions which seldom hold. Both the low-estimate 17 and the highestimate studies [18] [19] [20] [21] [22] sought for evidence of a compensatory drop in the observed data at age 70 years, but their approaches were different. Figure 1 compares the study designs, whereas Figure 2 compares the resulting, contemporary, incidence rates for Funen and Danish nonscreening areas.
The low-estimate study 17 was based on observing women born in 1923-1934 who were all invited for screening at age 59-70 years and followed for 5-14 years after end-ofscreening (parallelogram in Figure 1 ). Women aged <59 years, born after 1934, could not be observed for 5 years after end-of-screening. Here, both the initial excess incidence due to screening and the subsequent compensatory drop were observed in the same cohorts; and the excess incidence (59-69 years) and the compensatory drop (70-79 years) in Funen compared to nonscreening areas were clearly manifested in the age-specific incidence rates in Figure 2 using birth cohort 1932 as an example.
An analysis such as that by Jørgensen et al. 22 on the other hand, attempted to study the compensatory drop not only in women born in 1923-1934 (truly screened cohorts), but also in women born in 1913-1922 (never-screened cohorts; top part of the rectangle in Figure 1 ). Never-screened women can by definition not experience a compensatory drop. Moreover, they entered the analysis at an advanced age when the incidence in unscreened women is highest (Figure 2 , birth cohort 1922 as an example). This contamination of truly screened with high-risk never-screened cohorts helps explain why ageperiod incidence shows no decrease at age 70 years. The initial excess incidence, on the other hand, was studied on cohorts that included women born after 1934 (bottom part of the rectangle in Figure 1) . Hence, the two principal incidence phenomena in screening were addressed by studying different birth cohorts. This only makes sense if these cohorts (i) had the same risk of breast cancer and (ii) were screened the same number of times and at similar ages. When these assumptions do not hold, and they do not, 27 the excess incidence cannot be directly compared to the compensatory drop. In the age-period analysis, the excess incidence during screening (50-69 years) was still evident but the decrease at age 70 years appeared much smaller than in the birthcohort analysis (at 70-74 years), or nonexistent (at 75-79 years; Figure 2 , dashed lines). In high-estimate studies, this pattern has been misinterpreted as evidence to refute the existence of a compensatory drop, 18, 19, 21 even though one clearly existed (see cohort 1932). Comparing the age-period and birth cohort-based study designs for estimating overdiagnosis in breast cancer screening. Examples based on studies by Jørgensen et al. 21 and Njor et al. 16 for Funen County. 
Conclusion
In conclusion, both low and high estimates of overdiagnosis could be suggested by the same data, and the estimates depend on the study design. This prioritizes the need for a careful scrutiny of the validity of the assumptions underpinning the estimates before reporting multiple estimates. The age-period analyses of breast cancer overdiagnosis suggesting very high frequencies of overdiagnosis rested on unmet assumptions. Studies should control for the background risk and include an informative selection of the studied population, as suggested recently in methodological work. Measures of the impact of overdiagnosis should be based on shared and unbiased methodological options.
